162 related articles for article (PubMed ID: 33712276)
1. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
Post CCB; Mens JWM; Haverkort MAD; Koppe F; Jürgenliemk-Schulz IM; Snyers A; Roeloffzen EMA; Schaake EE; Slot A; Stam TC; Beukema JC; van den Berg HA; Lutgens LCHW; Nijman HW; de Kroon CD; Kroep JR; Stiggelbout AM; Creutzberg CL
Gynecol Oncol; 2021 Jun; 161(3):727-733. PubMed ID: 33712276
[TBL] [Abstract][Full Text] [Related]
2. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
; Blinman P; Mileshkin L; Khaw P; Goss G; Johnson C; Capp A; Brooks S; Wain G; Kolodziej I; Veillard AS; O'Connell R; Creutzberg CL; Stockler MR
Br J Cancer; 2016 Nov; 115(10):1179-1185. PubMed ID: 27764842
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
4. Treatment preferences and involvement in treatment decision making of patients with endometrial cancer and clinicians.
Kunneman M; Pieterse AH; Stiggelbout AM; Nout RA; Kamps M; Lutgens LC; Paulissen J; Mattheussens OJ; Kruitwagen RF; Creutzberg CL
Br J Cancer; 2014 Aug; 111(4):674-9. PubMed ID: 24921911
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemoradiotherapy vs. radiotherapy alone in early-stage high-risk endometrial cancer: a systematic review and meta-analysis.
Jingjing H; Rui J; Hui P
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):833-840. PubMed ID: 30720192
[TBL] [Abstract][Full Text] [Related]
6. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study.
van Weelden WJ; Reijnen C; Eggink FA; Boll D; Ottevanger PB; van den Berg HA; van der Aa MA; Pijnenborg JMA
Eur J Cancer; 2020 Jul; 133():104-111. PubMed ID: 32454416
[TBL] [Abstract][Full Text] [Related]
7. Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma.
Elemam O; Abdelkhalek S; Abdelmoety D; Aboelnaga E; Baraka R; Zeeneldine A
Asian Pac J Cancer Prev; 2020 May; 21(5):1327-1332. PubMed ID: 32458640
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
Chapman BV; Swanick CW; Ning MS; Allen PK; Soliman PT; Westin SN; Pardeshi V; Broaddus RR; Lu KH; Jhingran A; Eifel PJ; Klopp AH
Gynecol Oncol; 2019 Jul; 154(1):22-28. PubMed ID: 31109659
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.
De Boer SM; Nout RA; Bosse T; Creutzberg CL
Expert Rev Anticancer Ther; 2019 Jan; 19(1):51-60. PubMed ID: 30295094
[TBL] [Abstract][Full Text] [Related]
10. Toxicity after adjuvant therapy for stage III uterine cancer.
Chen LC; Huang Y; Hou JY; Khoury-Collado F; Melamed A; St Clair CM; Tergas AI; Hur C; Hillyer GC; Hershman DL; Wright JD
Gynecol Oncol; 2020 Dec; 159(3):737-743. PubMed ID: 33008633
[TBL] [Abstract][Full Text] [Related]
11. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
12. Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?
Marnitz S; Köhler C; Gharbi N; Kunze S; Jablonska K; Herter J
Strahlenther Onkol; 2018 Nov; 194(11):965-974. PubMed ID: 30112692
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy in stage III endometrial cancer confined to the pelvis.
Albeesh R; Turgeon GA; Alfieri J; Mansure JJ; Fu L; Arseneau J; Zeng X; Jardon K; Gilbert L; Souhami L
Gynecol Oncol; 2019 Jan; 152(1):26-30. PubMed ID: 30473258
[TBL] [Abstract][Full Text] [Related]
14. Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study.
Marchetti C; Pisano C; Mangili G; Lorusso D; Panici PB; Silvestro G; Candiani M; Greggi S; Perniola G; Di Maio M; Pignata S
Oncology; 2011; 81(2):104-12. PubMed ID: 21986449
[TBL] [Abstract][Full Text] [Related]
15. Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer.
Moth E; McLachlan SA; Veillard AS; Muljadi N; Hudson M; Stockler MR; Blinman P
Lung Cancer; 2016 May; 95():8-14. PubMed ID: 27040845
[TBL] [Abstract][Full Text] [Related]
16. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
17. Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients.
Binder PS; Peipert JF; Kallogjeri D; Brooks RA; Massad LS; Mutch DG; Powell MA; Thaker PH; McCourt CK
Am J Obstet Gynecol; 2016 Dec; 215(6):766.e1-766.e9. PubMed ID: 27457116
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
Post CCB; de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger NPB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Kitchener HC; Nijman HW; Lutgens LCHW; Brooks S; Jürgenliemk-Schulz IM; Feeney A; Goss G; Fossati R; Ghatage P; Leary A; Do V; Lissoni AA; McCormack M; Nout RA; Verhoeven-Adema KW; Smit VTHBM; Putter H; Creutzberg CL
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(4):975-986. PubMed ID: 33129910
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.
Sinha S; Lazar A; Lam A; Anderson EM; Chen LM; Hsu IJ; Yoshida EJ
Gynecol Oncol; 2020 Oct; 159(1):30-35. PubMed ID: 32811681
[TBL] [Abstract][Full Text] [Related]
20. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
